By Elaine Rigoli
Tampa, Fla., July 31 - Transport Pharmaceuticals, Inc. has closed a $12.6 million extension of its series D financing round, bringing the total to $29.6 million.
This funding comes from existing investors and was co-led by The Carlyle Group and Quaker BioVentures, with participation by The Hillman Co.
The company said the additional funds will support its lead drug/device combination product for herpes labialis (cold sores).
Based in Philadelphia, Transport develops drug and medical devices for the topical treatment of dermatological conditions.
| Issuer: | Transport Pharmaceuticals, Inc.
|
| Issue: | Series D financing
|
| Amount: | $12.6 million
|
| Investors: | The Carlyle Group, Quaker BioVentures, The Hillman Co.
|
| Announcement date: | July 31
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
